KCNQ1抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using KCNQ1 mouse mAb against MCF-7 (1) and A431 (2) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of MCF-7 cells using KCNQ1 mouse mAb (green) and negative control (red).    

  
  

The KCNQ1 antibody targets the KCNQ1 protein, a voltage-gated potassium channel α-subunit encoded by the *KCNQ1* gene. KCNQ1. also known as Kv7.1. is critical for maintaining electrochemical gradients across cell membranes. It forms the pore of the slow delayed rectifier potassium channel (I_Ks) by co-assembling with regulatory β-subunits like KCNE1. This channel is essential for cardiac repolarization, particularly in the heart, where it regulates the duration of action potentials. Mutations in *KCNQ1* are linked to congenital long QT syndrome type 1 (LQT1), a cardiac arrhythmia disorder, and Jervell and Lange-Nielsen syndrome, which combines hearing loss with cardiac abnormalities. KCNQ1 dysfunction is also implicated in non-cardiac conditions, including diabetes and gastrointestinal disorders.

Antibodies against KCNQ1 are vital tools for studying its expression, localization, and functional roles. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding research on channelopathies and tissue-specific pathologies. In diagnostics, KCNQ1 antibodies help identify protein expression anomalies in patient samples, supporting personalized therapeutic strategies. Additionally, these antibodies contribute to exploring KCNQ1's dual roles as both a tumor suppressor and oncogene in certain cancers. Their specificity and reliability are crucial for dissecting molecular mechanisms underlying diseases and developing targeted therapies.